CRF Meeting will Feature Research Updates and Latest Devices for the Treatment of Valvular Heart Disease

 CRF Meeting will Feature Research Updates and Latest Devices for the Treatment of Valvular Heart Disease

WHAT:

TVT 2015 is a three-day course featuring the latest research and state-of-the-art techniques for transcatheter, aortic, and mitral valve therapies. This year’s conference will emphasize advanced imaging, bioskill demonstrations, and live case transmissions featuring the world’s leading experts. The agenda is now available online at: http://www.crf.org/tvt/the-conference/agenda.

Sessions showcasing the latest research will focus on research updates and new insights from mitral and transcatheter valve trials and registries. Among the highlights are: 

MitraClip: World-wide Data and New Insights

• EVEREST II 5-Year Report: Beyond the Top-Line Results

Ted E. Feldman

• EVEREST REALISM: High-Risk Cohort

Scott Lim

• EVEREST REALISM: Non–High-Risk Cohort

Saibal Kar

• New Insights From the GRASP Registry

Marco Barbanti

• New Insights From the TRAMI Registry

Stephan Baldus

• ACCESS EU Update

Francesco Maisano

• The European Sentinel Registry

Carlo Di Mario

 

The Latest Clinical Data: Follow-up Vignettes from EU TAVR Registries

• ADVANCE

Axel Linke

• UK Registry

Neil E. Moat

• FRANCE 2

Helene Eltchaninoff

• GARY

Thomas Walther

The Latest Clinical Data: Updates from the Randomized TAVR Trials and TVT

• PARTNER 5-Year Follow-up

1. Murat Tuzcu

• CoreValve US 2-Year Follow-up

Michael J. Reardon

• NOTION in All-Comers

Lars Sondergaard

• Insights From the US TVT Registry

John D. Carroll

The meeting will also examine new technologies for transcatheter and mitral valve therapies including:

• Direct and indirect annuloplasty/ventriculoplasty devices (Carillon Device, Cardioband, Mitralign Procedure, Valcare Mitral Annuloplasty System, Guided Delivery Systems)
• Transcatheter mitral valve replacement devices (Tiara, Fortis, CardiaQ, Tendyne, MValve, Cephea)
• Transcatheter devices (SAPIEN XT, CoreValve Classic, LOTUS,       Direct Flow, Symetis       ACURATE, JenaValve, Portico, Engager, CENTERA)
• Early stage TAVR systems and novel surgical valves (Venus A, Shanghai, Trinity, Valve Medical, Thubrikar, Syntheon, Sutureless Surgical Valves)
• Cerebral embolic protection devices (Sentinel Dual Filter Device, Keystone Deflector Device,
• New access site management systems (transfemoral and transapical)
• New valvuloplasty systems and other accessories

WHY:

Valvular heart disease affects a large number of people who require diagnostic procedures and long-term management. Many patients have no symptoms, but for others, if not treated, advanced heart valve disease can cause heart failure, stroke, blood clots, or death due to sudden cardiac arrest. Traditionally, valvular heart disease has been treated with surgical repair or replacement. Over the last several years, however, there have been important advances in concepts, tools, techniques, and patient selection for treatment of valvular heart disease using nonsurgical procedures. Transcatheter valve intervention offers the potential to reduce the procedural morbidity, mortality, and costs of surgical valve replacement or repair while accelerating patient recovery.

WHEN:         
June 4-6, 2015

WHERE:
Hilton Chicago
720 S. Michigan Ave.
Chicago, Illinois 

WHO:
The course directors for TVT 2015 are:

Martin B. Leon, MD
NewYork-Presbyterian Hospital/Columbia University Medical Center

Francesco Maisano, MD
UniversitätsSpital Zürich

Nicolo Piazza, MD, PhD
McGill University Health Center

Mark Reisman, MD
University of Washington Medical Center/Regional Heart Center 

Gregg W. Stone, MD
New York-Presbyterian Hospital/Columbia University Medical Center 

John G. Webb, MD
St. Paul's Hospital 

HOW TO REGISTER:
Media may apply for registration by emailing jromero@crf.org. 

For those unable to attend in person, reporters are eligible for access to Virtual TVT which provides live and on-demand viewing of the meeting sessions.